Buy Sorafenib (Nexavar) Brands Online from India

Buy Sorafenib (Nexavar) Brands Online from India, USA, Uk, Romania, and more...

[smwllgarcia01]

Soranib 200 mg tablets (Cipla) are prescribed for the treatment of advanced kidney or liver cancers. You can buy Soranib 200 mg online and Low price in India.

[smwllgarcia01]

Sorafenat 200 mg tablets (Natco) Diseases like lung and kidney cancer can be extremely dangerous and cure is expensive. you can buy sorafenat 200 mg tablet online and lowest price in India.

[smwllgarcia01]

Sorafenib (Nexavar) 200mg tablets ip are used to treat patients suffering from hepatocellular carcinoma (HCC), it is a very common type of liver cancer. You can buy generic Sorafenib (Nexavar) online from India, philippines, and Australia.

[smwllgarcia01]

Sorafenib cost uk

A final appraisal from the clinical and cost-effectiveness watchdog backs Nexavar (sorafenib) for use on NHS England for the treatment of patients with "advanced hepatocellular carcinoma (HCC) who have a Child-Pugh grade A liver impairment and who have failed or are unsuitable for surgical or loco-regional therapies".  Sorafenib (Nexavar), for liver cancer, sorafenib cost uk $57,232 in the UK but $49,715 in Spain and $44,543 in France

At the list price, the twice-daily oral drug costs £128 per day per patient, but Bayer has agreed a drug at an undisclosed discount to NHS England. It is the first and only approved first-line pharmacological treatment option for patients with advanced HCC and is estimated to extend life by at least three months.

NICE has rejected Nexavar for liver cancer multiple times - the last being in December 2016 when it concluded that the drug did not provide value for money for the NHS and so should stay within the CDF.

The news has been welcomed by patient groups. Andrew Langford, chief executive of the British Liver Trust, said: "Treatment options for patients with advanced liver cancer have been very limited, but this decision will make sorafenib…more easily available and bring greater long-term certainty for patients."

"Evidence shows that outcomes for people with advanced liver cancer are particularly poor, so any increase in length of life is very important," he added.

The re-evaluation is part of an ongoing process - now three quarters complete - to review drugs on the CDF and see if they should be upgraded to routine NHS use.

Out of 24 treatments under scrutiny, 18 have been approved in either final or draft guidance. The majority of these drugs are now available for routine use on the NHS, according to NICE.

Amanda Cunnington, head of patient access at Bayer UK, said the company recently submitted its new HCC drug Stivarga (regorafenib) for review by NICE and the Scottish Medicines Consortium (SMC) "with the hope to also provide the first approved second-line treatment option for patients with HCC, who have previously been treated with sorafenib".